Imatinib Combined with Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation versus Imatinib Alone for Chronic Myeloid Leukemia in Chronic Phase

Trial Profile

Imatinib Combined with Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation versus Imatinib Alone for Chronic Myeloid Leukemia in Chronic Phase

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Allogeneic stem cell therapy (Primary) ; Imatinib (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Aug 2017 Primary endpoint (overall survival) has not been met.
    • 01 Aug 2017 Primary endpoint (Event-free survival (EFS)) has not been met.
    • 01 Aug 2017 Results of 10 year followup published in the Annals of Hematology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top